Effects of Liraglutide on Kidney Function in Type 2 Diabetic Patients
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 4
Locations
Denmark
Study Type
Interventional
Intervention
Liraglutide
Placebo-liraglutide
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring liraglutide, victoza, GLP-1, kidney, diabetes, renal, diabetic nephropathy
Eligibility Criteria
Inclusion Criteria:
- Informed consent obtained before any trial-related activities.
- Male gender
- T2DM, diagnosed according to international guidelines
- Age 20-60 years, both included
- Body Mass Index (BMI): 20-32 kg/m2, both included
- Metformin treatment
- Albumin/creatinine ratio <25 mg/mmol
Exclusion Criteria:
- Known or suspected allergy to trial product or related products
- Previous participation in this trial
- Previous treatment with GLP-1 analogues or DPP-4 inhibitors
- Current treatment with any antidiabetic drug other than metformin
- Poorly regulated glycemic control (HbA1c > 8%)
- Impaired kidney function: estimated GFR < 70ml/min
- Impaired liver function: liver parameters exceed 2 times upper normal limit
- Subjects with active malignancy
- Severe cardiac insufficiency classified according to NYHA III-IV
- Unstable angina pectoris, acute myocardial infarction (AMI) within the last 12 months
- Severe, uncontrolled hypertension: sitting blood pressure (BP) > 180/110 mmHg
- Antihypertensive treatment consisting of more than two different pharmaceutical products
- Symptoms related to benign prostate hyperplasia
- Claustrophobia
- Any metal body implants
- History of pancreatitis, type 1 diabetes, gastroparesis or multiple endocrine neoplasia syndrome type 2
- Personal or family history of medullary thyroid carcinoma
- Any diseases judged by the investigator that could affect the trial
- Any medication judged by the investigator that could affect the trial
Sites / Locations
- Aarhus University Hospital, Department of Endocrinology and Diabetes
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Liraglutide
Placebo-liraglutide
Arm Description
1.2 mg liraglutide sc. (single-dose)
Placebo liraglutide sc. (single-dose)
Outcomes
Primary Outcome Measures
Glomerular Filtration Rate (51Cr-EDTA plasma clearance)
Secondary Outcome Measures
Renal Blood Flow (functional magnetic resonance imaging)
Renal electrolyte clearance
Sodium, potassium, calcium, lithium and osmotically active substances.
Excretion of kidney injury markers
Albumin, NGAL, KIM-1, angiotensinogen and 8-OHdG.
Plasma concentrations of various hormones
Angiotensin II, renin, aldosterone, atrial natriuretic peptide, catecholamines.
Full Information
NCT ID
NCT01664676
First Posted
August 10, 2012
Last Updated
February 27, 2014
Sponsor
University of Aarhus
Collaborators
Novo Nordisk A/S, University of Copenhagen
1. Study Identification
Unique Protocol Identification Number
NCT01664676
Brief Title
Effects of Liraglutide on Kidney Function in Type 2 Diabetic Patients
Official Title
A Randomised, Double-blinded, Cross-over Study Investigating the Short-term Impact of Liraglutide on Kidney Function in Diabetic Patients
Study Type
Interventional
2. Study Status
Record Verification Date
February 2014
Overall Recruitment Status
Completed
Study Start Date
December 2012 (undefined)
Primary Completion Date
February 2014 (Actual)
Study Completion Date
February 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Aarhus
Collaborators
Novo Nordisk A/S, University of Copenhagen
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Recent studies in rodents show that glucagon-like peptide-1 (GLP-1) analogues protect against diabetic nephropathy. We hypothesise that this is also the case in humans. This study will investigate the short-term effect of liraglutide (GLP-1 analogue) on the kidneys in type 2 diabetic patients. Impact on basic kidney physiological will be determined and kidney injury markers will be measured as surrogate parameters of kidney protection.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
liraglutide, victoza, GLP-1, kidney, diabetes, renal, diabetic nephropathy
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
11 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Liraglutide
Arm Type
Experimental
Arm Description
1.2 mg liraglutide sc. (single-dose)
Arm Title
Placebo-liraglutide
Arm Type
Placebo Comparator
Arm Description
Placebo liraglutide sc. (single-dose)
Intervention Type
Drug
Intervention Name(s)
Liraglutide
Other Intervention Name(s)
Victoza
Intervention Type
Drug
Intervention Name(s)
Placebo-liraglutide
Other Intervention Name(s)
Isotonic saline
Primary Outcome Measure Information:
Title
Glomerular Filtration Rate (51Cr-EDTA plasma clearance)
Time Frame
10-15 hours post-dose
Secondary Outcome Measure Information:
Title
Renal Blood Flow (functional magnetic resonance imaging)
Time Frame
15 hours post-dose
Title
Renal electrolyte clearance
Description
Sodium, potassium, calcium, lithium and osmotically active substances.
Time Frame
10-15 hours post-dose
Title
Excretion of kidney injury markers
Description
Albumin, NGAL, KIM-1, angiotensinogen and 8-OHdG.
Time Frame
0-10 hours and 10-15 hours post-dose
Title
Plasma concentrations of various hormones
Description
Angiotensin II, renin, aldosterone, atrial natriuretic peptide, catecholamines.
Time Frame
10-15 hours post-dose
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Informed consent obtained before any trial-related activities.
Male gender
T2DM, diagnosed according to international guidelines
Age 20-60 years, both included
Body Mass Index (BMI): 20-32 kg/m2, both included
Metformin treatment
Albumin/creatinine ratio <25 mg/mmol
Exclusion Criteria:
Known or suspected allergy to trial product or related products
Previous participation in this trial
Previous treatment with GLP-1 analogues or DPP-4 inhibitors
Current treatment with any antidiabetic drug other than metformin
Poorly regulated glycemic control (HbA1c > 8%)
Impaired kidney function: estimated GFR < 70ml/min
Impaired liver function: liver parameters exceed 2 times upper normal limit
Subjects with active malignancy
Severe cardiac insufficiency classified according to NYHA III-IV
Unstable angina pectoris, acute myocardial infarction (AMI) within the last 12 months
Severe, uncontrolled hypertension: sitting blood pressure (BP) > 180/110 mmHg
Antihypertensive treatment consisting of more than two different pharmaceutical products
Symptoms related to benign prostate hyperplasia
Claustrophobia
Any metal body implants
History of pancreatitis, type 1 diabetes, gastroparesis or multiple endocrine neoplasia syndrome type 2
Personal or family history of medullary thyroid carcinoma
Any diseases judged by the investigator that could affect the trial
Any medication judged by the investigator that could affect the trial
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jens S Christiansen, Professor
Organizational Affiliation
Aarhus University Hospital, Department of Endocrinology and Diabetes
Official's Role
Principal Investigator
Facility Information:
Facility Name
Aarhus University Hospital, Department of Endocrinology and Diabetes
City
Aarhus
ZIP/Postal Code
8000
Country
Denmark
12. IPD Sharing Statement
Learn more about this trial
Effects of Liraglutide on Kidney Function in Type 2 Diabetic Patients
We'll reach out to this number within 24 hrs